Regeneron Pharmaceuticals (REGN) : The money flow analysis of Regeneron Pharmaceuticals (REGN) indicates a $2.84 million of outflow was on downticks, whereas, the investors on Monday gobbled up stocks worth $5.4 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.9 and so was the total money flow at $2.56 million. The bulls lapped up $0.1 million worth of block trades on upticks. The money flow was $0.1 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Regeneron Pharmaceuticals (REGN), pushing it down by -0.39% for the day. The stock slid $1.45 and traded at $372.36 during the day. Nonetheless, the stock is -1.58% over the previous weeks close.
Regeneron Pharmaceuticals, Inc. has dropped 9.67% during the last 3-month period . Year-to-Date the stock performance stands at -29.72%. Shares of Regeneron Pharmaceuticals, Inc. rose by 1.54% in the last five trading days and 4.1% for the last 4 weeks. In a related news, The Securities and Exchange Commission has divulged that Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, had unloaded 1,000 shares at an average price of $396.64 in a transaction dated on May 24, 2016. The total value of the transaction was worth $396,640.
Regeneron Pharmaceuticals (NASDAQ:REGN): stock turned positive on Monday. Though the stock opened at $374.8, the bulls momentum made the stock top out at $382.39 level for the day. The stock recorded a low of $370.92 and closed the trading day at $381.54, in the green by 2.07%. The total traded volume for the day was 763,616. The stock had closed at $373.81 in the previous days trading.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.